I agree, and think the delay may be around setting up the P3 trials for both products and they will potentially announce both readouts and new trials at the same time. Find it ridiculous the amount of hoops Mesoblast has to jump through in comparison to other products who get walk up starts after P3 trials completing.
However, I imagine MSB will also find it difficult to signal to the market in advance that two further P3 trials are required, as I am sure that would not be met with enthusiasm.
Puts a lot of pressure on the COVID trials being successful. Hopefully the VP was referring to one EU P3 and one US P3 and there is a chance that either CLB or CHF is able to get commercial approval without another P3.
I agree, and think the delay may be around setting up the P3...
-
- There are more pages in this discussion • 83 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |